Loading
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Previous close
$8.07
−$0.02 · -0.25%
Regular session · ET · Market data may be delayed.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Day range
Current $8.07
52-week range
Current $8.07
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
42
Fair Value
Sentiment
68
Bullish
Risk
47
Elevated Risk
Momentum
77
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Day range
Current $8.07
52-week range
Current $8.07
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 170.44M USD | 83.33M USD | 90.24M USD | 112.72M USD | 470.35M USD |
| Cost of goods sold | 20.3M USD | 33.57M USD | 37.21M USD | 54.55M USD | 51.83M USD |
| Gross profit | 150.14M USD | 49.76M USD | 53.03M USD | 58.18M USD | 418.51M USD |
| Research and development | 228.3M USD | 208.52M USD | 232.27M USD | 242.45M USD | 181.44M USD |
| Selling, general, and administrative | 82.86M USD | 76.62M USD | 88.49M USD | 85.28M USD | 79.33M USD |
| Operating expenses | 311.34M USD | 283.11M USD | 321.16M USD | 321.06M USD | 258.53M USD |
| Interest income | 12.27M USD | 174K USD | 25K USD | 342K USD | 719K USD |
| Interest expense | 45.01M USD | 12.66M USD | 6.86M USD | 23.25M USD | 26.28M USD |
| Depreciation and amortization | 15.62M USD | 16.22M USD | 17.32M USD | 12.91M USD | 9.56M USD |
| Operating income | −161.2M USD | −233.35M USD | −268.13M USD | −262.88M USD | 159.98M USD |
| Net income | −193.88M USD | −227.1M USD | −263.49M USD | −280.32M USD | 127.84M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.00
147.83% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI16.77M0.00%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI16.24M0.16%9.87B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM12.56M0.02%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF5.35M0.01%95.4B USD0.05%$235+0.80%
Fidelity Enhanced Small Cap ETFFESM3.84M0.06%6.41B USD0.28%$45.46+0.46%
iShares Biotechnology ETFIBB3.83M0.04%10.28B USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO3.68M0.03%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO2.63M0.01%18B USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
